Cancer drug development has long faced three persistent hurdles: tumors evolve resistance to therapies, clinical trials are costly and often fail due to difficulty identifying the right patients, and many promising drugs never reach patients because of toxicity or delivery issues. Onco-Innovations Ltd. (CBOE CA: ONCO) (OTCQB: ONNVF) is building a development strategy that combines novel biology, advanced drug delivery, and artificial intelligence to address these challenges simultaneously.
Onco-Innovations is advancing its lead candidate, ONC010, which pairs a PNKP inhibitor—a DNA Damage Response (DDR) target distinct from PARP—with a nanoparticle delivery system. DDR inhibitors have become a fast-growing category in oncology because cancer cells rely on DNA repair mechanisms to survive after radiation or chemotherapy. While PARP inhibitors opened the field, Onco-Innovations focuses on PNKP, a different target within the DDR pathway.
The company is also integrating artificial intelligence through its Inka Health subsidiary and the SynoGraph causal AI platform. These tools are intended to support patient stratification, clinical trial design, and evidence generation, aiming to improve the efficiency of drug development and increase the likelihood of success. By using AI to better identify which patients are likely to respond, the company hopes to reduce the high failure rates typical of oncology trials.
Onco-Innovations is currently conducting IND-enabling, manufacturing, and regulatory work for ONC010. The combination of a novel biological target, a nanoparticle delivery system designed to improve drug tolerability and efficacy, and AI-driven trial optimization represents an integrated approach to some of oncology's most persistent problems. This strategy could potentially lead to more effective treatments with fewer side effects, and more efficient clinical development.
For investors, the company’s approach reflects a broader trend in precision oncology, where biomarker-driven therapies, smarter trial design, and advanced delivery technologies are converging. Companies that can integrate these elements may be better positioned to overcome development challenges. The latest news and updates relating to ONNVF are available in the company’s newsroom at ibn.fm/ONNVF.
InvestorWire, a specialized communications platform, disseminated this press release on behalf of Onco-Innovations. InvestorWire is one of over 75 brands within the Dynamic Brand Portfolio @ IBN, providing services such as wire-grade press release syndication, article syndication to over 5,000 outlets, and social media distribution. For more information, visit https://www.InvestorWire.com. Please see full terms of use and disclaimers on the InvestorWire website at https://www.InvestorWire.com/Disclaimer.
